Sign in
4

Changes in Ownership

Denali Therapeutics Inc. Filed Acc 0001714899-22-000131

Director sold 20,000 shares at an average $31.61 ($632,282)

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Tessier-Lavigne Marc Director 2022-08-23 Sale −19,900 $31.61 $629,039 1,930,456 D: show line 1 in the form
Tessier-Lavigne Marc Director 2022-08-23 Sale −100 $32.43 $3,243 1,930,356 D: show line 2 in the form
Open-market sales · 20,000 sh · avg $31.61 · $632,282
Loading xslF345X03/wf-form4_166146545134466.xml…